1. Home
  2. PGY vs IMNM Comparison

PGY vs IMNM Comparison

Compare PGY & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pagaya Technologies Ltd.

PGY

Pagaya Technologies Ltd.

HOLD

Current Price

$21.85

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$21.71

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGY
IMNM
Founded
2016
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PGY
IMNM
Price
$21.85
$21.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
9
Target Price
$39.86
$31.44
AVG Volume (30 Days)
2.5M
2.9M
Earning Date
02-12-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,245,946,000.00
$9,679,000.00
Revenue This Year
$28.75
N/A
Revenue Next Year
$17.23
$11.53
P/E Ratio
N/A
N/A
Revenue Growth
28.33
N/A
52 Week Low
$8.27
$5.15
52 Week High
$44.99
$25.30

Technical Indicators

Market Signals
Indicator
PGY
IMNM
Relative Strength Index (RSI) 40.60 57.90
Support Level $22.72 $19.37
Resistance Level $24.06 $22.57
Average True Range (ATR) 1.31 1.48
MACD 0.01 0.04
Stochastic Oscillator 16.63 45.30

Price Performance

Historical Comparison
PGY
IMNM

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: